What Coiled Therapeutics does

Coiled Therapeutics plc is a clinical-stage precision oncology company developing first-in-class therapeutics for high-risk cancers. It was spun out from A2A Pharmaceuticals, Inc. in 2025 and completed a reverse takeover of Roquefort Therapeutics in March 2026 to acquire exclusive worldwide rights to its lead asset, AO-252 — a first-in-class, oral, brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3). AO-252 is currently in a Phase I clinical trial (NCT06136884) in the United States, with encouraging early clinical activity reported in ovarian and endometrial cancer patients, and the company is targeting material data readouts by Q4 2026 to support expansion cohorts in prostate and ovarian cancer and to enable partnering discussions with major pharmaceutical companies. The company leverages the proprietary SCULPT AI/ML-driven de novo drug design platform inherited from A2A Pharmaceuticals to discover and optimise compounds against coiled-coil and other structurally complex oncogenic proteins.

The company's broader pipeline includes a STAT-6 targeted siRNA programme for Th2-driven inflammatory conditions such as asthma, fibrosis, eczema, and allergic disease, representing a dual indication strategy spanning oncology and immunology. Business model mechanics are those of a pre-revenue clinical-stage biopharma: there are no commercial products, pricing is not applicable, and future revenue is expected to derive from licensing AO-252 and potentially the STAT-6 programme to pharmaceutical partners following clinical proof-of-concept. The company is incorporated in England as Coiled Therapeutics plc, headquartered in London, listed on the London Stock Exchange AIM market under ticker COIL, and cross-traded on the US OTCQB Venture Market under ticker COTXF, with a market capitalisation of approximately £43.15 million as of 24 June 2026.

Name

Coiled Therapeutics

Legal name

Coiled Therapeutics plc

Website

https://coiledplc.com

Company type

Public

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Coiled Therapeutics plc is a clinical-stage precision oncology company developing AO-252, a first-in-class oral brain-penetrant TACC3 inhibitor in Phase I trials for solid tumours, alongside a STAT-6 siRNA programme for inflammatory diseases, using an AI/ML-driven drug design platform spun out from A2A Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Precision oncology therapeutics
• Cancer drug development
• AI drug discovery
• Small molecule inhibitors
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-Revenue / Pipeline Development: Clinical-stage oncology company with no commercial products or revenue. Revenue generation is contingent on successful clinical development and regulatory approval of AO-252 and the STAT-6 programme. Future revenue streams may include product sales, licensing agreements, and partnerships with pharmaceutical companies.

Distribution channels1 record

Marketing channels4 records

Core offering

Coiled Therapeutics is a clinical-stage precision oncology company developing first-in-class therapeutics targeting TACC3 and STAT-6 for high-risk cancers and inflammatory diseases. Its lead asset AO-252 is an oral brain-penetrant small molecule TACC3 inhibitor currently in Phase I clinical trials (NCT06136884) for solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. The pipeline is supported by the proprietary SCULPT AI/ML-driven de novo drug design platform licensed from A2A Pharmaceuticals.

Product overview

Coiled Therapeutics is a clinical-stage precision oncology company advancing a pipeline of first-in-class therapeutics for high-risk cancers. The company's core portfolio consists of two programs: AO-252, a first-in-class TACC3 inhibitor currently in Phase I clinical trials for advanced solid tumours, and the STAT-6 program targeting immunology indications using siRNA technology. The company leverages AI/ML-driven de novo drug design platforms developed by A2A Pharmaceuticals to discover and develop therapeutics targeting coiled-coil and structurally complex oncogenic targets.

Differentiator

Problem solved

Functional benefit

Products and services

• AO-252 First-in-class oral brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3) currently in Phase I clinical trials (NCT06136884) for the treatment of advanced solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. AO-252 triggers severe DNA damage leading to cytoplasmic DNA leakage and activation of innate immune responses via the cGAS/STING pathway, while inhibiting multiple protein-protein interactions including DNA-PK, PARP1, BRCA, KU70, KIFC1, MBD2, and HDAC2.
• STAT-6 Program STAT-6 targeted program using siRNA technology for immunology indications including asthma, fibrosis, eczema, and allergic disease. Differentiated approach to inhibit IL-4/IL-13 signalling and Th2 differentiation, offering advantages over existing upstream therapies such as Dupixent.

Quantifiable outcome

• Phase I clinical trial active with encouraging early clinical activity observed in ovarian and endometrial patients
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Professor Guru SonpavdecoreStrategic or Co-development Partner · 17 June 2026Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Professor Sonpavde is an oncology heavyweight bringing extensive clinical trial experience and will shape clinical strategy including expansion cohort design, indication selection, and combination therapy plans.
• Dr Alexander SpiracoreStrategic or Co-development Partner · 17 June 2026Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Dr Spira is an oncology expert who will contribute to clinical strategy including expansion cohort design, indication selection, and combination therapy plans.
• Ozgur SahincoreStrategic or Co-development Partner · 8 June 2026Appointed as Scientific Advisor to provide expertise in support of the company's scientific and clinical development programmes.
• Roquefort TherapeuticscoreStrategic or Co-development Partner · 1 March 2026Roquefort Therapeutics completed a reverse takeover with Coiled Therapeutics, Inc. resulting in Roquefort being renamed Coiled Therapeutics plc. The transaction valued at approximately £32 million in shares plus £8.5 million placing involved Roquefort acquiring exclusive worldwide rights to AO-252. The company is now listed on AIM under ticker COIL.
• A2A Pharmaceuticals, Inc.coreStrategic or Co-development Partner · 1 January 2025Coiled Therapeutics was spun out from A2A Pharmaceuticals in 2025. The company leverages A2A's proprietary AI/ML-driven de novo design platform called SCULPT. The worldwide license to AO-252 was acquired from Coiled Therapeutics, Inc., a spin-out of A2A Pharmaceuticals, and Chaemin Lim, PhD, a founding team member and former CSO at A2A Pharmaceuticals, now serves as Chief Technology Officer at Coiled Therapeutics.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Foghorn Therapeutics: Clinical-stage precision oncology biotech targeting chromatin biology and protein-protein interactions, including coiled-coil and structurally complex targets. Highly comparable to Coiled's approach against undruggable oncogenic proteins and its platform-based discovery model.
• Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric and mutation-targeted small molecules against historically difficult oncology targets. Comparable to Coiled in scale, development stage, and first-in-class precision oncology positioning.
• Relay Therapeutics: Clinical-stage precision oncology company combining computational approaches with structure-based drug design against precision oncology targets, including protein motion-based design. Comparable to Coiled's AI/ML-driven design philosophy against complex targets.
• Repare Therapeutics: Clinical-stage precision oncology company targeting synthetic lethal vulnerabilities in cancer using a platform-based discovery approach. Comparable in clinical-stage precision oncology positioning, multi-indication strategy, and platform-driven pipeline development.
• Cogent Biosciences: Clinical-stage precision oncology company developing targeted therapies against oncogenic drivers with a focus on smaller, indication-focused trials and partnering optionality. Comparable to Coiled's clinical-stage, indication-specific development strategy.
• Erasca: Clinical-stage precision oncology company developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable as a clinical-stage precision oncology peer with multiple programmes and a focus on historically difficult-to-drug oncogenic targets.

Broad incumbents

• Schrödinger: Computational drug discovery company combining physics-based modelling with AI/ML for small molecule discovery across multiple therapeutic areas. Comparable to Coiled's use of computational and AI-driven drug design for structurally complex targets, though Schrödinger operates at much greater scale and breadth.
• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning for pharmaceutical R&D. Comparable to Coiled's AI/ML-driven discovery philosophy, though operating at much broader scale and across multiple therapeutic areas.
• Exscientia: AI-driven precision medicine company using end-to-end AI platforms for small molecule drug discovery. Comparable to Coiled's AI/ML-driven de novo design approach, though Exscientia operates at greater scale with broader pipeline and partner network.

Emerging players

• Alnylam Pharmaceuticals: Leading siRNA therapeutics company with multiple approved and clinical-stage RNA interference products across rare and specialty diseases. Comparable to Coiled's STAT-6 siRNA programme as the most established peer in the siRNA modality space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coiled Therapeutics